#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Acquired haemophilia Vernal keratoconjunctivitis Philadelphia chromosome positive Meningitis meningococcal Mantle cell lymphoma stage III Leukaemia Cutaneous calcification Deafness neurosensory Mantle cell lymphoma recurrent Immune thrombocytopenia Lung adenocarcinoma Drug eruption Bronchopulmonary aspergillosis Mitochondrial encephalomyopathy Gaucher's disease type III More trials…

    Learn about Rare Diseases

    Mitochondrial myopathy – Life with Disease Alagille syndrome – Trials in Disease Andersen-Tawil syndrome – Treatment Skin angiosarcoma Hereditary angioedema with C1 esterase inhibitor deficiency – Treatment Mucopolysaccharidosis I – Life with Disease Acquired haemophilia Paraneoplastic neurological syndrome – Basic Information Angiosarcoma Prader-Willi syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    F770/05 Pembrolizumab Dasatinib IHMA-2121908-1 Avapritinib Vixarelimab Macrogol 4000 Bms-986458 Fianlimab Levamlodipine Succinate Bcmacp03 Nesolicaftor Ethanol, Anhydrous PUCOTENLIMAB Stiripentol OBI-821 Ciclosporin Darolutamide Dextromethorphan Hydrobromide Nemvaleukin Alfa More therapies…

    Learn about Your Condition

    Takayasu's arteritis Sepsis Aortic valve stenosis Papillary thyroid cancer Plasma cell myeloma Ebola disease Periodontitis Tuberculosis Osteosarcoma recurrent Glomerulonephritis chronic Dyslipidaemia Mitral valve incompetence Escherichia infection Follicular lymphoma stage IV Right ventricular dysfunction More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Diffuse large B-cell lymphoma recurrent

  • Glofitamab plus drug combination for relapsed/refractory large B‑cell lymphoma in high‑risk second‑line patients eligible for CAR‑T therapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma recurrent
    • Diffuse large B-cell lymphoma refractory
    Investigated Drugs:
    • Axicabtagene Ciloleucel
    • Glofitamab
    • Lisocabtagene Maraleucel
    Germany

  • Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia recurrent
    • Chronic lymphocytic leukaemia refractory
    • Follicular lymphoma stage II
    Investigated Drugs:
    • N-[4-({[(1R,4R)-4-Hydroxy-4-Methylcyclohexyl]Methyl}Amino)-3- Nitrobenzene-1-Sulfonyl]-4-(2-{(2S)-2-[2-(Propan-2-Yl)Phenyl]Pyrrolidin1-Yl}-7-Azaspiro[3.5]Nonan-7-Yl)-2-[(1H-Pyrrolo[2,3-B]Pyridin-5- Yl)Oxy]Benzamide
    • BGB-16673
    • Mosunetuzumab
    Germany Italy Poland

  • Study on the Effectiveness and Safety of AZD0486 for Adults with Relapsed or Refractory Non-Hodgkin Lymphoma

    Recruiting

    2 1 1
    Investigated Diseases:
    • Follicular lymphoma
    • Diffuse large B-cell lymphoma recurrent
    • Diffuse large B-cell lymphoma refractory
    Investigated Drugs:
    • Human Igg4 Kappa Monoclonal Antibody Against Cd3 And Cd19
    Denmark France Germany Italy Spain Sweden

  • Study on the Effectiveness and Safety of Cytarabine, Tafasitamab, and Lenalidomide for Patients with Relapsed Diffuse Large B-Cell Lymphoma

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • B-cell unclassifiable lymphoma high grade
    • Diffuse large B-cell lymphoma stage I
    • Diffuse large B-cell lymphoma stage II
    Investigated Drugs:
    • Tafasitamab
    • Axicabtagene Ciloleucel
    • Polatuzumab Vedotin
    Poland

  • Study of Rituximab, Gemcitabine, Dexamethasone, and Platinum with or without Selinexor for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Not recruiting

    4 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma recurrent
    • Diffuse large B-cell lymphoma refractory
    Investigated Drugs:
    • Filgrastim
    • Gemcitabine
    • Selinexor
    Italy Poland Spain

  • Study of Mosunetuzumab and Polatuzumab Vedotin for Patients with Diffuse Large B-Cell Lymphoma After Initial Treatment or in Elderly/Unfit Untreated Patients

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Mosunetuzumab
    • Polatuzumab Vedotin
    • Tocilizumab
    Poland Spain
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!